Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

25.0%

1 terminated/withdrawn out of 4 trials

Success Rate

66.7%

-19.8% vs industry average

Late-Stage Pipeline

50%

2 trials in Phase 3/4

Results Transparency

50%

1 of 2 completed trials have results

Key Signals

1 recruiting1 with results

Enrollment Performance

Analytics

Phase 4

2(50.0%)

N/A

1(25.0%)

Phase 2

1(25.0%)

4Total

Phase 4(2)

N/A(1)

Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials

NCT07145736Phase 4Recruiting

Moxidectin Versus Ivermectin as Mass Drug Administration for the Control of Onchocerciasis and Other Neglected Tropical Diseases

Role: collaborator

NCT04035174Not ApplicableWithdrawn

Evaluation of the Diagnosis Performances of DEC LTS-2 Skin Patch for Onchocerciasis in Central Africa

Role: lead

NCT04049851Phase 2Completed

Clinical Trial Evaluating the Safety and Efficacy of Moxidectin 2 mg Ivermectin-controlled in Loa Loa Microfilaremic Patients

Role: lead

NCT05085665Phase 4Completed

Loiasis Cross-reactive Antigenemia and Treatment-related Adverse Events

Role: collaborator

All 4 trials loaded